Introduction
The theme of this meeting is peculiarly apt to the policy of our new Section, namely, to concentrate upon questions of clinical oncology and to stimulate interchange between the clinical contribution and experimental cancer research. Tumour immunology and the prospects of an immunotherapy have a long and varied history. A central topic of the German literature of pathology in the last century was the extent to which, if indeed at all, signs might be detected, by histological or other methods, of a cellular somatic reaction against the growth of autochthonous tumours. Such endeavours were largely inconclusive or negative, although much later (in the 1920s) came the pioneering observations of J B Murphy, at the Rockefeller Institute, of a possibly defensive lymphocyte infiltration in many tumours of animals. Tumour immunology was my first love when I entered the cancer field in 1929. At that time, much work was ill-conceived or ephemeral, and the same year saw Woglom's (1929) classic review in which the celebrated American oncologist surveyed some hundreds of papers, only to find a mere handful likely to hold any lasting or permanent interest. From that day to this, tumour immunology has waxed and waned. The present intense revival is partly due to the modem development of immunological techniques of great sophistication and delicacy, and partly to the concurrent emergence of new ideasoften of the utmost brilliance; but it also reflects the continuing and fascinating logic of the immune approach. It is natural that these developments should hold out fresh prospects, at long last, of a useful immunotherapy, and it is vital that these developments be pursued with the utmost vigour, both clinically and experimentally, always provided that such work is without prejudice to the investigation of other forms of attack. In spite of a momentary over-optimism in certain quarters, it is probable that those who have made the greatest contributions to recent tumour immunology, and who possess the deepest knowledge of it, are perhaps the most cautious and least sanguine. Hence the prospects of immunotherapy must be assayed with utmost balance, and our purpose must be, as in every other department of cancer research, to stimulate both clinical interest and new experiments, while simultaneously repressing unjustified enthusiasm and prejudgment. Tumour-associated antigens which elicit immune responses in the host have been conclusively demonstrated in experimental tumours of many types including those induced by chemical carcinogens and viruses as well as spontaneously arising tumours where the etiology is unknown. These antigens in experimental tumours have frequently been described as tumour-specific transplantation antigens because of their capacity to elicit immunity against tumour cells transplanted into syngeneic recipients, but since they are also recognized by the autochthonous host, a more apt description is tumour rejection antigen. Tumours induced by chemical or physical agents express individually distinct tumour antigens so that immunization against one tumour does not
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